Company intelligence / Profile preview

eXIthera

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

eXIthera's lead candidate, EP-7041, has completed Phase 1 clinical trials in healthy volunteers and patients with end-stage renal disease (ESRD). Results demonstrated a favorable safety profile, no significant bleeding events, and dose-dependent inhibition of Factor XIa activity. The program is moving toward Phase 2 development for the prevention of thrombosis.

Therapeutic areas: CardiovascularNephrology
Modalities: Small molecule
Industry: Biotech

Partnerships

Catalyst Biosciences

Beyond the preview

Go deeper on eXIthera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eXIthera.

Explore the full profile